There is one thing in common with the major studies that drew attention at this year's Annual Conference of the American Society of Clinical Oncology (ASCO 2023). It has achieved successful results in adjuvant therapy targeting early cancer where surgery is possible. New drugs used in terminal cancers, such as metastasis and recursation, have already surpassed the standard treatment in early cancers.

The CDK 4/6 inhibitor Kisqali has demonstrated post-operative adjuvant treatment in early breast cancer. The risk of recurrence or death was reduced by 25% with a three-year dose of Kisqali after surgery. The blockbuster immuno-oncology drug Keytruda completes the treatment journey not only after non-small